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Background
Human African trypanosomiasis (HAT), also known as
sleeping sickness, is a parasitic tropical disease. It
progresses from stage 1 or early phase, when parasites are
present in blood and/or lymph, to stage 2 or late stage
when parasites have invaded the central nervous system
(CNS). As treatment depends on the stage of disease, there
is an urgent need for tools that can efficiently discriminate
the two stages of HAT. In this context, we hypothesized
that markers of brain damage discovered by proteomic
strategies as well as cytokines and chemokines could indi-
vidually or in combination indicate the CNS invasion by
the parasite.
Methods
Patients consulting a trypanosomiasis treatment centre in
D.R. Congo and infected by Trypanosoma brucei gambiense
were investigated in this study. They were staged on the
basis of the cerebrospinal fluid (CSF) white blood cell
count (WBC) and presence of the parasite in CSF. A total
of 100 CSF samples, comprising 21 stage 1 (< 5 WBC/μL),
8 intermediate stage (between 5 and 20 WBC/μL) and 71
stage 2 (> 20 WBC/μL), were analysed. CSF concentra-
tions of H-FABP, GSTP-1 and S100β were measured by
enzyme-linked immunosorbent assays (ELISA). The levels
of thirteen cytokines and chemokines (IL-1ra, IL-1β, IL-6,
IL-8, IL-9, IL-10, G-CSF, MIP-1β, VEGF, IFN-γ, MCP-1,
TNF-α and IP-10) were determined by bead suspension
arrays.
Results
IP-10 was the best individual molecule able to distinguish
between stage 1 and stage 2 patients with a sensitivity of
91% and a specificity of 100%. Multivariate analysis
defined a panel characterized of GSTP1 (> 5.05 ng/ml),
IP-10 (> 2204 pg/ml) and IL-8 (> 102.4 pg/ml), where
stage 2 patients were identified with a sensitivity of 97%
and a specificity of 100%, when at least one of the 3 mol-
ecules is above the cut-off.
Conclusion
This study highlights the value of IP-10 as a single biomar-
ker for staging HAT patients. Its further combination with
GSTP1 and IL-8 results in a panel that efficiently identifies
stage 2 HAT patients.
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